Breast Cancer Research and Treatment

, Volume 147, Issue 1, pp 221–222 | Cite as

Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time?

  • Orit Kaidar-PersonEmail author
  • Philip Poortmans
  • Suzanne Klimberg
  • Joanne Haviland
  • Birgitte Offersen
  • Riccardo Audisio
  • John Yarnold
Letter to the Editor

We would like to comment on the manuscript written by Esserman and colleagues [1] regarding the application of a decision analytic framework for adoption of clinical trial results. It is true that due to the prevalence of breast cancer, any management decision concerning its treatment may have significant implications concerning medical resources use and costs. However, this also holds true for any mistake or hasty decision that might carry a heavy price on public health in the long term.

If the purpose of the model presented in the article aimed to describe an analytic framework, then for the purpose of proof of concept, the statistical analysis should be applied first on treatments for which long-term follow-up is available, in order to prove and validate that the model can predict the same results as in the reality of daily practice. The use of the currently available TARGIT-A trial data to evaluate this model is inappropriate since follow-up in the TARGIT-A trial is immature [2, 3]...


High Local Recurrence Rate Adjuvant Hormonal Treatment Hasty Decision Staff Safety Decision Analytic Framework 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest



  1. 1.
    Esserman LJ, Alvarado MD, Howe RJ et al (2014) Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat 144(2):371–378CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Vaidya JS, Wenz F, Bulsara M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. doi: 10.1016/S0140-6736(13)61950-9 CrossRefPubMedGoogle Scholar
  3. 3.
    Vaidya JS, Joseph DJ, Tobias JS et al (2010) Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376(9735):91–102CrossRefPubMedGoogle Scholar
  4. 4.
    Veronesi U, Orecchia R, Maisonneuve P et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14:1269–1277CrossRefPubMedGoogle Scholar
  5. 5.
    Hughes KS, Schnaper LA, Bellon JR et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Leonardi MC, Maisonneuve P, Mastropasqua MG et al (2013) Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol 106(1):21–27CrossRefPubMedGoogle Scholar
  8. 8.
    Smith GL, Xu Y, Buchholz TA et al (2012) Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 307(17):1827–1837CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Kaidar-Person O, Yarnold J, Offersen BV, Poortmans P (2014) Is current evidence about intraoperative partial breast irradiation sufficient for broad implementation in clinical practice? Eur J Surg Oncol 27. doi: 10.1016/j.ejso.2014.03.014

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Orit Kaidar-Person
    • 1
    Email author
  • Philip Poortmans
    • 2
  • Suzanne Klimberg
    • 3
    • 4
    • 5
  • Joanne Haviland
    • 6
  • Birgitte Offersen
    • 7
  • Riccardo Audisio
    • 8
  • John Yarnold
    • 9
  1. 1.Division of OncologyRambam Health Care CampusHaifaIsrael
  2. 2.Institute VerbeetenTilburgThe Netherlands
  3. 3.Division of Breast Surgical Oncology, Department of Surgery, Winthrop P Rockefeller Cancer InstituteUniversity of Arkansas for Medical Sciences (UAMS)Little RockUSA
  4. 4.Arkansas Breast Cancer Research Program (ABCRP), Winthrop P Rockefeller Cancer InstituteUniversity of Arkansas for Medical Sciences (UAMS)Little RockUSA
  5. 5.Department of PathologyUniversity of Arkansas for Medical SciencesLittle RockUSA
  6. 6.Faculty of Health SciencesUniversity of SouthamptonSouthamptonUK
  7. 7.Department of OncologyAarhus University HospitalAarhusDenmark
  8. 8.St Helens Teaching HospitalUniversity of LiverpoolSt HelensUK
  9. 9.Division of Radiotherapy and ImagingThe Institute of Cancer ResearchLondonUK

Personalised recommendations